News

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed […]

Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.

These beaten-down Dividend Kings, trading near their 2026 lows, offer income, rebound potential, and Wall Street-backed upside for patient investors.

ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q1 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy declined 2.39% (net of fees), trailing the Russell 1000 Value Index’s 2.10%. The performance was positively affected by stock selection in industrials and consumer discretionary, along […]

If you are wondering whether Abbott Laboratories at around US$87.41 is a bargain or a value trap, it helps to step back and look at what the current price really implies. The stock has gained 3.5% over the past week, although it remains down 4.7% over the past month and has declined 29.6% year to date and 32.1% over the last year, which may have shifted how investors view its risk and potential reward. Recent coverage has focused on Abbott Laboratories as a large healthcare stock with a long...

Investing.com -- The United States has suspended visa issuance for any travelers who have visited South Sudan, the Democratic Republic of Congo (DRC), or Uganda within 21 days of their planned arrival, according to an exclusive report by The Wall Street Journal on Friday.

When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.

MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.

While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.

Carillon Tower Advisers, an investment management company, released its first-quarter 2026 investor letter for the “Carillon Eagle Growth & Income Fund”. A copy of the letter is available to download here. The first quarter of 2026 was volatile due to market shifts, including increased geopolitical risk and inflation fears from rising energy prices. The S&P declined […]

Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best stocks to buy according to Goldman Sachs’ Conviction List. Goldman added UnitedHealth to its U.S. Conviction List on May 1, alongside Interactive Brokers, while removing Abbott Laboratories and Keysight Technologies. The firm said its conviction lists highlight stocks it views favorably for investment, and UnitedHealth’s inclusion […]

Abbott Laboratories (NYSE:ABT) is expanding its presence in health tech with new diagnostics and wearable products, including the Lingo biomarker monitoring device. The company is also increasing R&D activity in cardiovascular diagnostics, aiming to broaden its role in earlier detection and ongoing monitoring of heart related conditions. These product moves come as attention on Abbott has recently centered on earnings, insider activity, and the Exact Sciences acquisition rather than its...

ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?

They have increased their payouts for a combined 171 years straight.

ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.

The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

In the last year, multiple insiders have substantially increased their holdings of Abbott Laboratories ( NYSE:ABT...

Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This might have investors contemplating their next move.

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

These three Dividend Aristocrats under $100 offer steady payouts, reasonable payout ratios, and analyst-backed upside potential.